PriceTargets.com logo

NASDAQ:AVIR - Atea Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.33
  • Forecasted Upside: 55.25 %
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.30 As of 01/14/2022 01:00 AM ET
+0.30 (1.20%)

This chart shows the closing price for AVIR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atea Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVIR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVIR

Analyst Price Target is $11.33
▲ +55.25% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Atea Pharmaceuticals in the last 3 months. The average price target is $11.33, with a high forecast of $16.00 and a low forecast of $7.00. The average price target represents a 55.25% upside from the last price of $7.30.

This chart shows the closing price for AVIR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Atea Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/6/2022Morgan StanleyDowngradeEqual Weight ➝ Underweight$14.00 ➝ $7.00High
12/16/2021SVB LeerinkReiterated RatingHold$11.00High
11/18/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$11.00Low
10/20/2021SVB LeerinkLower Price TargetOutperform$60.00 ➝ $20.00High
10/19/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$61.00 ➝ $16.00High
10/18/2021JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$56.00 ➝ $61.00High
10/5/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$55.00Medium
9/9/2021SVB LeerinkInitiated CoverageOutperform$60.00High
8/18/2021Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $37.00Low
6/3/2021Morgan StanleyLower Price TargetOverweight$82.00 ➝ $35.00Low
4/6/2021Morgan StanleyBoost Price TargetOverweight$49.00 ➝ $82.00High
1/29/2021JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 ➝ $66.00High
11/24/2020Evercore ISIInitiated CoverageOutperformHigh
11/24/2020Morgan StanleyInitiated CoverageOverweight$49.00Low
11/24/2020JPMorgan Chase & Co.Initiated CoverageOverweight$45.00Low
11/24/2020William BlairInitiated CoverageOutperform$60.00Medium
(Data available from 1/17/2017 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/19/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
11/18/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Atea Pharmaceuticals logo
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $7.30
Low: $7.01
High: $7.30

50 Day Range

MA: $8.59
Low: $7.30
High: $11.50

52 Week Range

Now: $7.30
Low: $7.01
High: $94.17

Volume

1,137,002 shs

Average Volume

1,087,860 shs

Market Capitalization

$606.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Atea Pharmaceuticals?

The following sell-side analysts have issued research reports on Atea Pharmaceuticals in the last year: JPMorgan Chase & Co., Morgan Stanley, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for AVIR.

What is the current price target for Atea Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Atea Pharmaceuticals in the last year. Their average twelve-month price target is $11.33, suggesting a possible upside of 55.3%. JPMorgan Chase & Co. has the highest price target set, predicting AVIR will reach $16.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $7.00 for Atea Pharmaceuticals in the next year.
View the latest price targets for AVIR.

What is the current consensus analyst rating for Atea Pharmaceuticals?

Atea Pharmaceuticals currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AVIR, but not buy more shares or sell existing shares.
View the latest ratings for AVIR.

How do I contact Atea Pharmaceuticals' investor relations team?

The company's listed phone number is 857-284-8891 and its investor relations email address is [email protected] The official website for Atea Pharmaceuticals is www.ateapharma.com.